The Company is a developer, manufacturer and marketer of next-generation life-science tools and integrated systems for the analysis of genetic variation and biological function.
BATS data provided in real-time. NYSE, NASDAQ and NYSEMKT data delayed 15 minutes.
Real-Time prices provided by BATS. Market data provided by Interactive Data.
Company fundamental data provided by Morningstar. Earnings Estimates, Analyst Ratings and Key Statistics provided by Zacks.
SEC Filings and Insider Transactions provided by Edgar Online.
Powered and implemented by Interactive Data Managed Solutions. Terms & Conditions
RSS Headlines
Fool UK
Recs
Illumina has a technical lead making it the sequencing "Rule Maker" in this industry. The main competitors are Roche/454 and Life Sciences/SOLiD. 454 still has a nice technology and is quite complimentary to the depth of coverage available with Illumina. SOLiD appears to be a dead-end however.
There are a few newcomers that may become "Rule Breakers", including PacBio and Ion torrent, but both of these technologies are seeking niches where the overwhelming depth of coverage and read-length offered by Illumina will not get them hammered.
Both research and medicine are rapidly becoming dependent on deep sequencing. We are now moving into a time where DNA sequencing is truly as important as a microscope. Illumina has a daunting lead. Even giants can become complacent, and this market has numerous "Davids" looking to pick up some scraps.
Until a very long sequence read technology is developed that can reliably produce single reads of over 10,000 bases, it is Illumina's market to loose. The wide-moat is filling....